NCT04550897 (BM7PE) is a Phase 1, PHASE2 clinical trial of BM7PE in Colorectal Cancer Metastatic, sponsored by Oslo University Hospital.

Who is sponsoring NCT04550897?

NCT04550897 is sponsored by Oslo University Hospital.

What drugs are being tested in NCT04550897?

Interventions in NCT04550897: BM7PE.

What condition does NCT04550897 study?

NCT04550897 studies Colorectal Cancer Metastatic.

Is NCT04550897 still recruiting?

NCT04550897 is currently status unknown. Last updated 22 March 2023.

Last reviewed 2023-03-22 · How we verify

NCT04550897: BM7PE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients

Status unknown Phase 1, PHASE2 Last updated 22 March 2023

What this trial tests

Phase 1, PHASE2 trial testing BM7PE in Colorectal Cancer Metastatic in 60 participants. Status unknown.

Timeline

31 August 2020

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Oslo University Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	60
Start date	31 August 2020
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Norway

Drugs / interventions tested

BM7PE — full drug profile →

Conditions studied

Colorectal Cancer Metastatic — all drugs for Colorectal Cancer Metastatic →

Sponsor

Oslo University Hospital

Who can join

18 and older, any sex, with Colorectal Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase 1/2 study will evaluate the safety, tolerance and dose of BM7PE treating patients with colorectal cancer who have progressed to standard cell therapy or cannot tolerate such therapy. The study starts as a phase 1 study with the aim of assessing the final dose for this group of patients. Based on the results, the study will continue into a phase 2. The phase 2 study aim to examine overall survival ≥ 9.3 months.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy.
Lee DH, Choi S, Park Y, Jin HS. · · 2021 · cited 53× · PMID 34681277 · DOI 10.3390/ph14101053
Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.
Ren X, Lin S, Guan F, Kang H. · · 2024 · cited 30× · PMID 38725856 · DOI 10.7150/ijbs.93806
Antibody-Based Immunotoxins for Colorectal Cancer Therapy.
Sanz L, Ibáñez-Pérez R, Guerrero-Ochoa P, Lacadena J, et al · · 2021 · cited 18× · PMID 34829955 · DOI 10.3390/biomedicines9111729

Verify or expand the search:

Other recruiting trials for Colorectal Cancer Metastatic

Currently open trials in the same condition.

NCT07328087 — COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer · EARLY_PHASE1 · recruiting
NCT07462650 — Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer · Phase 1, PHASE2 · recruiting
NCT07193862 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Meta · EARLY_PHASE1 · recruiting
NCT07172282 — INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases · EARLY_PHASE1 · recruiting
NCT06889610 — A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. · Phase 2 · recruiting

Other Oslo University Hospital trials

Trials by the same sponsor.

NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04550897 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
Last refreshed: 22 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04550897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing